Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions -A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Arcaro, Alessia ^a   Pirozzi, Flora ^b   Angelini, Annalisa ^c   Chimenti, Cristina ^d   Crotti, Lia ^e,f   Giordano, Carla ^d   Mancardi, Daniele ^g   Torella, Daniele ^h   Tocchetti, Carlo G ^b  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; DISEASE CONTROL; MACHINERY; MOLECULES; PHYSIOLOGY;

ANTIOXIDANT PROPERTIES; EFFECTIVE THERAPY; EXTRACELLULAR MATRIX DEPOSITION; PATHOPHYSIOLOGY; REACTIVE OXYGEN AND NITROGEN SPECIES; SIGNALING MOLECULES; SIGNALING PATHWAYS; THERAPEUTIC INTERVENTION;

CARDIOLOGY;

ALDOSTERONE ANTAGONIST; ALLOPURINOL; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CARVEDILOL; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELAMIPRETIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENKEPHALINASE INHIBITOR; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOAMINE OXIDASE INHIBITOR; NEUROHORMONE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; RANOLAZINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RESVERATROL; SUPEROXIDE DISMUTASE; UNINDEXED DRUG; NITROGEN;

ANTIOXIDANT ACTIVITY; CALCIUM CELL LEVEL; CYTOLOGY; ENERGY TRANSFER; EXTRACELLULAR MATRIX; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; MACHINE; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SCAVENGING SYSTEM; SIGNAL TRANSDUCTION; SUDDEN CARDIAC DEATH; SYSTEMIC DISEASE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CHEMISTRY; HOMEOSTASIS; ITALY; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; PROGNOSIS;

ANTIOXIDANTS; CALCIUM; HEART FAILURE; HOMEOSTASIS; HUMANS; ITALY; MITOCHONDRIA; MYOCARDIUM; MYOCYTES, CARDIAC; NITROGEN; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROGNOSIS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84961377007     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/6353469     Document Type: Review

References (176)

1. E. Braunwald, Thewar against heart failure: the Lancet lecture, The Lancet, vol. 385, no. 9970, pp. 812-824, 2015.
2. J. J. McMurray, S. Adamopoulos, S. D. Anker et al. , ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, European Journal of Heart Failure, vol. 14, pp. 803-869, 2012.
3. C. W. Yancy, M. Jessup, B. Bozkurt et al. , 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on PracticeGuidelines, Circulation, vol. 128, no. 16, pp. e240-e327, 2013.
4. G. Tarone, J. -L. Balligand, J. Bauersachs et al. , Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology, European Journal of Heart Failure, vol. 16, no. 5, pp. 494-508, 2014.
5. A. S. Go, D. Mozaffarian, V. L. Roger et al. , Heart disease and stroke statistics-2014 update: a report from the American Heart Association, Circulation, vol. 129, no. 3, pp. e28-e292, 2014.
6. S. J. Greene, G. C. Fonarow, M. Vaduganathan, S. S. Khan, J. Butler, and M. Gheorghiade, The vulnerable phase after hospitalization for heart failure, Nature Reviews Cardiology, vol. 12, no. 4, pp. 220-229, 2015.
7. J. O. Mudd andD. A. Kass, Tackling heart failure in the twenty first century, Nature, vol. 451, no. 7181, pp. 919-928, 2008.
8. J. N. Cohn, T. B. Levine, and M. T. Olivari, Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure,The New England Journal of Medicine, vol. 311, no. 13, pp. 819-823, 1984.
9. B. Pitt, F. Zannad,W. J. Remme et al. , The effect of spironolactone on morbidity and mortality in patients with severe heart failure, The New England Journal of Medicine, vol. 341, no. 10, pp. 709-717, 1999.
10. M. A. Pfeffer, E. Braunwald, L. A. Moyé et al. , Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial,The New England Journal of Medicine, vol. 327, no. 10, pp. 669-677, 1992.
11. M. Packer, A. J. S. Coats,M. B. Fowler et al. , Effect of carvedilol on survival in severe chronic heart failure, The New England Journal of Medicine, vol. 344, no. 22, pp. 1651-1658, 2001.
12. L. H. Opie and J. Knuuti, The adrenergic-fatty acid load in heart failure, Journal of the American College of Cardiology, vol. 54, no. 18, pp. 1637-1646, 2009.
13. L. Zhang, J. S. Jaswal, J. R. Ussher et al. , Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy, Circulation: Heart Failure, vol. 6, no. 5, pp. 1039-1048, 2013.
14. V. G. Dávila-Román, G. Vedala, P. Herrero et al. , Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy, Journal of the American College of Cardiology, vol. 40, no. 2, pp. 271-277, 2002.
15. M. N. Sack, T. A. Rader, S. Park, J. Bastin, S. A. McCune, and D. P. Kelly, Fatty acid oxidation enzyme gene expression is downregulated in the failing heart, Circulation, vol. 94, no. 11, pp. 2837-2842, 1996.
16. J. J. Lehman and D. P. Kelly, Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth, Heart Failure Reviews, vol. 7, no. 2, pp. 175-185, 2002.
17. G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, and W. C. Stanley, Myocardial fatty acid metabolism in health and disease, Physiological Reviews, vol. 90, no. 1, pp. 207-258, 2010.
18. L. Nascimben, J. S. Ingwall, B. H. Lorell et al. , Mechanisms for increased glycolysis in the hypertrophied rat heart, Hypertension, vol. 44, no. 5, pp. 662-667, 2004.
19. M. Taha and G. D. Lopaschuk, Alterations in energy metabolism in cardiomyopathies, Annals of Medicine, vol. 39, no. 8, pp. 594-607, 2007.
20. M. Brownlee, Biochemistry and molecular cell biology of diabetic complications, Nature, vol. 414, no. 6865, pp. 813-820, 2001.
21. M. A. Aon, C. G. Tocchetti, N. Bhatt, N. Paolocci, and S. Cortassa, Protective mechanisms of mitochondria and heart function in diabetes, Antioxidants & Redox Signaling, vol. 22, no. 17, pp. 1563-1586, 2015.
22. J. R. Burgoyne, S. -I. Oka, N. Ale-Agha, and P. Eaton, Hydrogen peroxide sensing and signaling by protein kinases in the cardiovascular system, Antioxidants & Redox Signaling, vol. 18, no. 9, pp. 1042-1052, 2013.
23. R. G. Weiss, G. Gerstenblith, and P. A. Bottomley, ATP flux through creatine kinase in the normal, stressed, and failing human heart, Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 808-813, 2005.
24. C. G. Tocchetti, V. Caceres, B. A. Stanley et al. , GSH or palmitate preserves mitochondrial energetic/redox balance, preventing mechanical dysfunction in metabolically challenged myocytes/hearts from type 2 diabetic mice, Diabetes, vol. 61, no. 12, pp. 3094-3105, 2012.
25. C. Tocchetti, M. Molinaro, T. Angelone et al. , Nitroso-redox balance and modulation of basal myocardial function: an update from the Italian Society of Cardiovascular Research (SIRC), Current Drug Targets, vol. 16, no. 8, pp. 895-903, 2015.
26. E. Takimoto and D. A. Kass, Role of oxidative stress in cardiac hypertrophy and remodeling, Hypertension, vol. 49, no. 2, pp. 241-248, 2007.
27. C. Nediani, L. Raimondi, E. Borchi, and E. Cerbai, Nitric oxide/reactive oxygen species generation and nitroso/redox imbalance in heart failure: from molecular mechanisms to therapeutic implications, Antioxidants and Redox Signaling, vol. 14, no. 2, pp. 289-331, 2011.
28. M. T. Ziolo and D. M. Bers, The real estate of NOS signaling: location, location, location, Circulation Research, vol. 92,no. 12, pp. 1279-1281, 2003.
29. E. Ortona, P. Margutti, P. Matarrese, F. Franconi, and W. Malorni, Redox state, cell death and autoimmune diseases: a gender perspective, Autoimmunity Reviews, vol. 7, no. 7, pp. 579-584, 2008.
30. J. M. Hare and J. S. Stamler, NO/redox disequilibrium in the failing heart and cardiovascular system, Journal of Clinical Investigation, vol. 115, no. 3, pp. 509-517, 2005.
31. J. R. Burgoyne, H. Mongue-Din, P. Eaton, and A. M. Shah, Redox signaling in cardiac physiology and pathology, Circulation Research, vol. 111, no. 8, pp. 1091-1106, 2012.
32. D. B. Sawyer, D. A. Siwik, L. Xiao,D. R. Pimentel, K. Singh, and W. S. Colucci, Role of oxidative stress in myocardial hypertrophy and failure, Journal of Molecular and Cellular Cardiology, vol. 34, no. 4, pp. 379-388, 2002.
33. F. J. Giordano, Oxygen, oxidative stress, hypoxia, and heart failure, The Journal of Clinical Investigation, vol. 115, no. 3, pp. 500-508, 2005.
34. C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah, NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure, Cardiovascular Research, vol. 71, no. 2, pp. 208-215, 2006.
35. C. X. C. Santos, N. Anilkumar, M. Zhang, A. C. Brewer, and A. M. Shah, Redox signaling in cardiac myocytes, Free Radical Biology and Medicine, vol. 50, no. 7, pp. 777-793, 2011.
36. M. Zhang, A. Perino, A. Ghigo, E. Hirsch, and A. M. Shah, NADPH oxidases in heart failure: poachers or gamekeepers? Antioxidants and Redox Signaling, vol. 18, no. 9, pp. 1024-1041, 2013.
37. J. K. Bendall, A. C. Cave, C. Heymes, N. Gall, and A. M. Shah, Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice, Circulation, vol. 105, no. 3, pp. 293-296, 2002.
38. T. Ago, J. Kuroda, J. Pain,C. Fu,H. Li, and J. Sadoshima, Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes, Circulation Research, vol. 106, no. 7, pp. 1253-1264, 2010.
39. Y. H. Looi, D. J. Grieve, A. Siva et al. , Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction, Hypertension, vol. 51, no. 2, pp. 319-325, 2008.
40. J. A. Byrne, D. J. Grieve, J. K. Bendall et al. , Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy, Circulation Research, vol. 93, no. 9, pp. 802-805, 2003.
41. C. Heymes, J. K. Bendall, P. Ratajczak et al. , Increasedmyocardial NADPH oxidase activity in human heart failure, Journal of the American College of Cardiology, vol. 41,no. 12,pp. 2164-2171, 2003.
42. C. Nediani, E. Borchi, C. Giordano et al. , NADPH oxidasedependent redox signaling in human heart failure: relationship between the left and right ventricle, Journal of Molecular and Cellular Cardiology, vol. 42, no. 4, pp. 826-834, 2007.
43. J. M. Zimmet and J. M. Hare, Nitroso-redox interactions in the cardiovascular system, Circulation, vol. 114, no. 14, pp. 1531-1544, 2006.
44. K. M. Minhas, R. M. Saraiva, K. H. Schuleri et al. , Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy, Circulation Research, vol. 98, no. 2, pp. 271-279, 2006.
45. C. Doerries, K. Grote, D. Hilfiker-Kleiner et al. , Critical role of the NAD(P)H oxidase subunit p47ααα? for left ventricular remodeling/dysfunction and survival after myocardial infarction, Circulation Research, vol. 100, no. 6, pp. 894-903, 2007.
46. W. F. Saavedra, N. Paolocci, M. E. St. John et al. , Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underliesmechanoenergetic uncoupling in the failing heart, Circulation Research, vol. 90, no. 3, pp. 297-304, 2002.
47. L. B. Stull, M. K. Leppo, L. Szweda, W. D. Gao, and E. Marbán, Chronic treatmentwith allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy, Circulation Research, vol. 95, no. 10, pp. 1005-1011, 2004.
48. L. Zhao, B. M. Roche, J. L. Wessale et al. , Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment, Life Sciences, vol. 82, no. 9-10, pp. 495-502, 2008.
49. B. Halliwell and J. M. Gutteridge, Free Radicals in Biology and Medicine, Oxford University Press, Oxford, UK, 4th edition, 2007.
50. Y. F. Pung, W. J. Sam, J. P. Hardwick et al. , The role of mitochondrial bioenergetics and reactive oxygen species in coronary collateral growth, The American Journal of Physiology-Heart and Circulatory Physiology, vol. 305, no. 9, pp. H1275-H1280, 2013.
51. D. C. Wallace, W. Fan, and V. Procaccio, Mitochondrial energetics and therapeutics, Annual Review of Pathology, vol. 5, pp. 297-348, 2010.
52. S. H. Kwon, D. R. Pimentel, A. Remondino, D. B. Sawyer, andW. S. Colucci, H2O2 regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways, Journal of Molecular and Cellular Cardiology, vol. 35, no. 6, pp. 615-621, 2003.
53. K. M. Haizlip, N. Hiranandani, B. J. Biesiadecki, and P. M. L. Janssen, Impact of hydroxyl radical-induced injury on calcium handling and myofilament sensitivity in isolated myocardium, Journal of Applied Physiology, vol. 113, no. 5, pp. 766-774, 2012.
54. F. Tullio, C. Angotti, M. -G. Perrelli, C. Penna, and P. Pagliaro, Redox balance and cardioprotection, Basic Research in Cardiology, vol. 108, no. 6, article 392, 2013.
55. T. Ide, H. Tsutsui, S. Kinugawa et al. , Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium, Circulation Research, vol. 85, no. 4, pp. 357-363, 1999.
56. T. Ide, H. Tsutsui, S. Kinugawa et al. , Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium, Circulation Research, vol. 86, no. 2, pp. 152-157, 2000.
57. N. Kaludercic, J. Mialet-Perez, N. Paolocci, A. Parini, and F. Di Lisa, Monoamine oxidases as sources of oxidants in the heart, Journal of Molecular and Cellular Cardiology, vol. 73, pp. 34-42, 2014.
58. G. Agati, E. Azzarello, S. Pollastri, and M. Tattini, Flavonoids as antioxidants in plants: location and functional significance, Plant Science, vol. 196, pp. 67-76, 2012.
59. M. Rizwan, I. Rodriguez-Blanco, A. Harbottle, M. A. Birch-Machin, R. E. B. Watson, and L. E. Rhodes, Tomato paste rich in lycopene protects against cutaneous photodamage in humans in vivo: a randomized controlled trial, British Journal of Dermatology, vol. 164, no. 1, pp. 154-162, 2011.
60. C. Nathan, Inducible nitric oxide synthase: what difference does it make? Journal of Clinical Investigation, vol. 100, no. 10, pp. 2417-2423, 1997.
61. L. A. Barouch, R. W. Harrison, M. W. Skaf et al. , Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms, Nature, vol. 416, no. 6878, pp. 337-340, 2002.
62. P. B. Massion, O. Feron, C. Dessy, and J. -L. Balligand, Nitric oxide and cardiac function: ten years after, and continuing, Circulation Research, vol. 93, no. 5, pp. 388-398, 2003.
63. C. E. Sears, E. A. Ashley, and B. Casadei, Nitric oxide control of cardiac function: is neuronal nitric oxide synthase a key component? Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 359, no. 1446, pp. 1021-1044, 2004.
64. C. G. Tocchetti, B. A. Stanley, C. I. Murray et al. , Playing with cardiac redox switches: the HNÓ way to modulate cardiac function, Antioxidants & Redox Signaling, vol. 14, no. 9, pp. 1687-1698, 2011.
65. O. Feron, C. Dessy, D. J. Opel, M. A. Arstall, R. A. Kelly, and T. Michel, Modulation of the endothelial nitric-oxide synthase-caveolin interaction in cardiacmyocytes: implications for the autonomic regulation of heart rate, Journal of Biological Chemistry, vol. 273, no. 46, pp. 30249-30254, 1998.
66. J. M. Hare, R. A. Lofthouse, G. J. Juang et al. , Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure, Circulation Research, vol. 86, no. 10, pp. 1085-1092, 2000.
67. P. M. Hassoun, F. S. Yu, J. J. Zulueta, A. C. White, and J. J. Lanzillo, Effect of nitric oxide and cell redox status on the regulation of endothelial cell xanthine dehydrogenase, American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 268, no. 5, pp. L809-L817, 1995.
68. C. G. Cote, F. -S. Yu, J. J. Zulueta, R. J. Vosatka, and P. M. Hassoun, Regulation of intracellular xanthine oxidase by endothelial-derived nitric oxide, American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 271, no. 5, pp. 869-874, 1996.
69. E. Takimoto, H. C. Champion, M. Li et al. , Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling fromchronic pressure load, The Journal of Clinical Investigation, vol. 115, no. 5, pp. 1221-1231, 2005.
70. C. -A. Chen, C. -H. Lin, L. J. Druhan, T. -Y. Wang, Y. -R. Chen, and J. L. Zweier, Superoxide induces endothelial nitric-oxide synthase protein thiyl radical formation, a novel mechanism regulating eNOS function and coupling, The Journal of Biological Chemistry, vol. 286, no. 33, pp. 29098-29107, 2011.
71. J. K. Bendall, N. J. Alp, N. Warrick et al. , Stoichiometric relationships between endothelial tetrahydrobiopterin, eNOS activity and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTPCH and eNOS over-expression, Circulation Research, vol. 97, no. 9, pp. 864-871, 2005.
72. L. M. Bevers, B. Braam, J. A. Post et al. , Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase, Hypertension, vol. 47, no. 1, pp. 87-94, 2006.
73. A. L. Moens, E. Takimoto, C. G. Tocchetti et al. , Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy, Circulation, vol. 117, no. 20, pp. 2626-2636, 2008.
74. N. Paolocci, R. Biondi, M. Bettini et al. , Oxygen radicalmediated reduction in basal and agonist-evoked no release in isolated rat heart, Journal of Molecular and Cellular Cardiology, vol. 33, no. 4, pp. 671-679, 2001.
75. B. M. Gaston, J. Carver, A. Doctor, and L. A. Palmer, Snitrosylation signaling in cell biology, Molecular Interventions, vol. 3, no. 5, pp. 253-263, 2003.
76. M. T. Ziolo and S. R. Houser, Abnormal Ca2+ cycling in failing ventricular myocytes: role of NOS1-mediated nitrosoredox balance, Antioxidants and Redox Signaling, vol. 21, no. 14, pp. 2044-2059, 2014.
77. A. J. Lokuta, N. A. Maertz, S. V. Meethal et al. , Increased nitration of sarcoplasmic reticulum Ca2+-ATPase in human heart failure, Circulation, vol. 111, no. 8, pp. 988-995, 2005.
78. T. Katori, S. Donzelli, C. G. Tocchetti et al. , Peroxynitrite and myocardial contractility: in vivo versus in vitro effects, Free Radical Biology and Medicine, vol. 41, no. 10, pp. 1606-1618, 2006.
79. J. Sun, E. Picht,K. S. Ginsburg, D. M. Bers,C. Steenbergen, and E. Murphy, Hypercontractile female hearts exhibit increased Snitrosylation of the L-type Ca2+ channel α1 subunit and reduced ischemia/reperfusion injury, Circulation Research, vol. 98, no. 3, pp. 403-411, 2006.
80. T. M. Sarkela, J. Berthiaume, S. Elfering, A. A. Gybina, and C. Giulivi, Themodulation of oxygen radical production by nitric oxide in mitochondria, The Journal of Biological Chemistry, vol. 276, no. 10, pp. 6945-6949, 2001.
81. P. Je?zek and L. Hlavatá, Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism, International Journal of Biochemistry and Cell Biology, vol. 37,no. 12,pp. 2478-2503, 2005.
82. D. Cesselli, I. Jakoniuk, L. Barlucchi et al. , Oxidative stressmediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy, Circulation Research, vol. 89, no. 3, pp. 279-286, 2001.
83. L. Xiao, D. R. Pimental, J. K. Amin, K. Singh, D. B. Sawyer, and W. S. Colucci, MEK1/2-ERK1/2 mediates α1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes, Journal of Molecular and Cellular Cardiology, vol. 33, no. 4, pp. 779-787, 2001.
84. K. Tanaka, M. Honda, and T. Takabatake, Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte, Journal of the American College of Cardiology, vol. 37, no. 2, pp. 676-685, 2001.
85. K. Nakamura, K. Fushimi, H. Kouchi et al. , Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II, Circulation, vol. 98, no. 8, pp. 794-799, 1998.
86. S. Delbosc, J. -P. Cristol, B. Descomps, A. Mimran, and B. Jover, Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress, Hypertension, vol. 40, no. 2, pp. 142-147, 2002.
87. J. K. Amin, L. Xiao, D. R. Pimental et al. , Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes, Journal of Molecular and Cellular Cardiology, vol. 33, no. 1, pp. 131-139, 2001.
88. G. M. Kuster, D. R. Pimentel, T. Adachi et al. , α-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on ras, Circulation, vol. 111, no. 9, pp. 1192-1198, 2005.
89. A. Sabri, H. H. Hughie, and P. A. Lucchesi, Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes, Antioxidants and Redox Signaling, vol. 5, no. 6, pp. 731-740, 2003.
90. I. Kehat and J. D. Molkentin, Molecular pathways underlying cardiac remodeling during pathophysiological stimulation, Circulation, vol. 122, no. 25, pp. 2727-2735, 2010.
91. V. C. Tu, J. J. Bahl, andQ. M. Chen, Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase, Journal of Pharmacology and Experimental Therapeutics, vol. 300, no. 3, pp. 1101-1110, 2002.
92. D. Sorescu and K. K. Griendling, Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure, Congestive Heart Failure, vol. 8, no. 3, pp. 132-140, 2002.
93. F. G. Spinale, Bioactive peptide signalingwithin themyocardial interstitium and the matrix metalloproteinases, Circulation Research, vol. 91, no. 12, pp. 1082-1084, 2002.
94. T. -H. Cheng, P. -Y. Cheng, N. -L. Shih, I. -B. Chen, D. L. Wang, and J. -J. Chen, Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts, Journal of the American College of Cardiology, vol. 42, no. 10, pp. 1845-1854, 2003.
95. D. A. Siwik, P. J. Pagano, and W. S. Colucci, Oxidative stress regulates collagen synthesis andmatrixmetalloproteinase activity in cardiac fibroblasts, American Journal of Physiology: Cell Physiology, vol. 280, no. 1, pp. C53-C60, 2001.
96. D. A. Siwik and W. S. Colucci, Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium, Heart Failure Reviews, vol. 9, no. 1, pp. 43-51, 2004.
97. D. M. Bers, Altered cardiac myocyte Ca regulation in heart failure, Physiology, vol. 21, no. 6, pp. 380-387, 2006.
98. A. V. Zima and L. A. Blatter, Redox regulation of cardiac calcium channels and transporters, Cardiovascular Research, vol. 71, no. 2, pp. 310-321, 2006.
99. K. Y. Xu, J. L. Zweier, and L. C. Becker, Hydroxyl radical inhibits sarcoplasmic reticulumCa2+-ATPase function by direct attack on theATP binding site, Circulation Research, vol. 80,no. 1, pp. 76-81, 1997.
100. L. Guerra, E. Cerbai, S. Gessi, P. A. Borea, andA. Mugelli, The effect of oxygen free radicals on calciumcurrent and dihydropyridine binding sites in guinea-pig ventricular myocytes, British Journal of Pharmacology, vol. 118, no. 5, pp. 1278-1284, 1996.
101. P. Kaplan, E. Babusikova, J. Lehotsky, and D. Dobrota, Free radical-induced protein modification and inhibition of Ca2+-ATPase of cardiac sarcoplasmic reticulum, Molecular and Cellular Biochemistry, vol. 248, no. 1-2, pp. 41-47, 2003.
102. C. G. Tocchetti, A. Carpi, C. Coppola et al. , Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction, European Journal of Heart Failure, vol. 16, no. 4, pp. 358-366, 2014.
103. R. Zhang, M. S. C. Khoo, Y. Wu et al. , Calmodulin kinase II inhibition protects against structural heart disease, Nature Medicine, vol. 11, no. 4, pp. 409-417, 2005.
104. J. R. Erickson, M. -L. A. Joiner, X. Guan et al. , A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation, Cell, vol. 133, no. 3, pp. 462-474, 2008.
105. R. Coppini, C. Ferrantini, L. Yao et al. , Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy, Circulation, vol. 127, no. 5, pp. 575-584, 2013.
106. H. Nakaya, Y. Takeda, N. Tohse, and M. Kanno, Mechanism of the membrane depolarization induced by oxidative stress in guinea-pig ventricular cells, Journal of Molecular and Cellular Cardiology, vol. 24, no. 5, pp. 523-534, 1992.
107. J. I. Goldhaber, Free radicals enhance Na+/Ca2+ exchange in ventricular myocytes, American Journal of PhysiologyHeart and Circulatory Physiology, vol. 271, no. 3,pp. H823-H833, 1996.
108. B. Pieske and S. R. Houser, [Na+]i handling in the failing human heart, Cardiovascular Research, vol. 57, pp. 874-886, 2003.
109. C. Maack, S. Cortassa, M. A. Aon, A. N. Ganesan, T. Liu, and B. ÓRourke, Elevated cytosolicNa+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes, Circulation Research, vol. 99, no. 2, pp. 172-182, 2006.
110. M. Kohlhaas, T. Liu, A. Knopp et al. , Elevated cytosolic Na+ increasesmitochondrial formation of reactive oxygen species in failing cardiac myocytes, Circulation, vol. 121, no. 14, pp. 1606-1613, 2010.
111. M. Canton, A. Skyschally, R. Menabo et al. , Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization, European Heart Journal, vol. 27, no. 7, pp. 875-881, 2006.
112. M. Canton, S. Menazza, F. L. Sheeran, P. Polverino De Laureto, F. Di Lisa, and S. Pepe, Oxidation of myofibrillar proteins in human heart failure, Journal of the American College of Cardiology, vol. 57, no. 3, pp. 300-309, 2011.
113. M. Packer, J. R. Carver, R. J. Rodeheffer et al. , Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group,The New England Journal of Medicine, vol. 325, no. 21, pp. 1468-1475, 1991.
114. D. L. Mann and M. R. Bristow, Mechanisms and models in heart failure: the biomechanical model and beyond, Circulation, vol. 111, no. 21, pp. 2837-2849, 2005.
115. J. I. Goldhaber and M. A. Hamilton, Role of inotropic agents in the treatment of heart failure, Circulation, vol. 121, no. 14, pp. 1655-1660, 2010.
116. G. Hasenfuss and J. R. Teerlink, Cardiac inotropes: current agents and future directions, European Heart Journal, vol. 32, no. 15, pp. 1838-1845, 2011.
117. L. Nagy, P. Pollesello, andZ. Papp, Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus, Journal of Cardiovascular Pharmacology, vol. 64, no. 3, pp. 199-208, 2014.
118. A. Arcaro, G. Lembo, and C. G. Tocchetti, Nitroxyl (HNO) for treatment of acute heart failure, Current Heart Failure Reports, vol. 11, no. 3, pp. 227-235, 2014.
119. N. Khaper and P. K. Singal, Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats, Journal of the American College of Cardiology, vol. 37, no. 5, pp. 1461-1466, 2001.
120. F. Stillitano, L. Sartiani, P. DePaoli, A. Mugelli, and E. Cerbai, Expression of the hyperpolarization-activated current, αf, in cultured adult rat ventricular cardiomyocytes and its modulation by hypertrophic factors, Pharmacological Research, vol. 57, no. 2, pp. 100-109, 2008.
121. K. Miyata, M. Rahman, T. Shokoji et al. , Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in ratmesangial cells, Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 2906-2912, 2005.
122. D. Sanz-Rosa, M. P. Oubina, E. Cediel et al. , Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences, Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1294-1301, 2005.
123. F. Zannad, J. J. V. McMurray, H. Krum et al. , Eplerenone in patients with systolic heart failure and mild symptoms, The New England Journal of Medicine, vol. 364, no. 1, pp. 11-21, 2011.
124. S. -B. Wang, D. B. Foster, J. Rucker, B. ÓRourke, D. A. Kass, and J. E. Van Eyk, Redox regulation of mitochondrial ATP synthase: implications for cardiac resynchronization therapy, Circulation Research, vol. 109, no. 7, pp. 750-757, 2011.
125. G. Tong, A. M. Aponte, M. J. Kohr, C. Steenbergen, E. Murphy, and J. Sun, Postconditioning leads to an increase in protein S-nitrosylation, American Journal of Physiology: Heart and Circulatory Physiology, vol. 306, no. 6, pp. H825-H832, 2014.
126. G. C. Fonarow, Role of carvedilol controlled-release in cardiovascular disease, Expert Review of CardiovascularTherapy, vol. 7, no. 5, pp. 483-498, 2009.
127. W. M. Book, Carvedilol: a nonselective β blocking agent with antioxidant properties, Congestive Heart Failure, vol. 8, no. 3, pp. 173-190, 2002.
128. T. L. Yue, P. J. Mckenna, J. L. Gu,H. Y. Cheng, R. R. Ruffolo Jr. , and G. Z. Feuerstein, Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells, Hypertension, vol. 22, no. 6, pp. 922-928, 1993.
129. N. Toda, Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics, Pharmacology andTherapeutics, vol. 100, no. 3, pp. 215-234, 2003.
130. S. A. Sorrentino, C. Doerries, C. Manes et al. , Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade, Journal of the American College of Cardiology, vol. 57, no. 5, pp. 601-611, 2011.
131. I. Ozakca, E. Arioglu-Inan, H. Esfahani et al. , Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage, The American Journal of Physiology-Heart and Circulatory Physiology, vol. 304, no. 9, pp. H1267-H1276, 2013.
132. D. M. Trappanese, Y. Liu, R. C. McCormick et al. , Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefitwith selective β1-blocker therapy, Basic Research in Cardiology, vol. 110, no. 1, article 456, 2015.
133. E. Takimoto, H. C. Champion, M. Li et al. , Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy, Nature Medicine, vol. 11, no. 2, pp. 214-222, 2005.
134. F. Hofmann, R. Feil, T. Kleppisch, and J. Schlossmann, Function of cGMP-dependent protein kinases as revealed by gene deletion, Physiological Reviews, vol. 86, no. 1, pp. 1-23, 2006.
135. D. A. Kass, H. C. Champion, and J. A. Beavo, Phosphodiesterase type 5: expanding roles in cardiovascular regulation, Circulation Research, vol. 101, no. 11, pp. 1084-1095, 2007.
136. A. Das, D. Durrant, F. N. Salloum, L. Xi, and R. C. Kukreja, PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer, Pharmacology andTherapeutics, vol. 147, pp. 12-21, 2015.
137. P. W. Fisher, F. Salloum, A. Das, H. Hyder, and R. C. Kukreja, Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity, Circulation, vol. 111, no. 13, pp. 1601-1610, 2005.
138. J. J. V. McMurray, M. Packer, A. S. Desai et al. , Angiotensinneprilysin inhibition versus enalapril in heart failure, The New England Journal of Medicine, vol. 371, no. 11, pp. 993-1004, 2014.
139. E. Bisping, P. Wakula, M. Poteser, and F. R. Heinzel, Targeting cardiac hypertrophy: toward a causal heart failure therapy, Journal of Cardiovascular Pharmacology, vol. 64, no. 4, pp. 293-305, 2014.
140. A. Cordle, J. Koenigsknecht-Talboo, B. Wilkinson, A. Limpert, and G. Landreth, Mechanisms of statin-mediated inhibition of small G-protein function, The Journal of Biological Chemistry, vol. 280, no. 40, pp. 34202-34209, 2005.
141. M. Aviram, M. Rosenblat, C. L. Bisgaier, and R. S. Newton, Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation, Atherosclerosis, vol. 138, no. 2, pp. 271-280, 1998.
142. A. M. Andres, G. Hernandez, P. Lee et al. , Mitophagy is required for acute cardioprotection by simvastatin, Antioxidants & Redox Signaling, vol. 21, no. 14, pp. 1960-1973, 2014.
143. M. Luo and M. E. Anderson, Mechanisms of altered Ca2+ handling in heart failure, Circulation Research, vol. 113, no. 6, pp. 690-708, 2013.
144. Y. Song, J. C. Shryock, S. Wagner, L. S. Maier, and L. Belardinelli, Blocking late sodium current reduces hydrogen peroxideinduced arrhythmogenic activity and contractile dysfunction, Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 1, pp. 214-222, 2006.
145. S. Wagner, N. Dybkova, E. C. Rasenack et al. , Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels, Journal of Clinical Investigation, vol. 116, no. 12, pp. 3127-3138, 2006.
146. D. M. Bers, Excitation-Contraction Coupling and Cardiac Contractile Force, Kluwer Academic Publishers, Dordrecht, The Netherlands, 2nd edition, 2001.
147. O. Zeitz, A. E. Maass, P. Van Nguyen et al. , Hydroxyl radicalinduced acute diastolic dysfunction is due to calcium overload via reverse-mode Na+-Ca2+ exchange, Circulation Research, vol. 90, no. 9, pp. 988-995, 2002.
148. H. Hwang, J. M. Arcidi Jr. , S. L. Hale et al. , Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts, Circulation, vol. 120, no. 1, pp. S16-S21, 2009.
149. Y. Wu, Y. Song, L. Belardinelli, and J. C. Shryock, The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction, Journal of Pharmacology and ExperimentalTherapeutics, vol. 330, no. 2, pp. 550-557, 2009.
150. H. N. Sabbah, M. P. Chandler, T. Mishima et al. , Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure, Journal of Cardiac Failure, vol. 8, no. 6, pp. 416-422, 2002.
151. S. Rastogi,V. G. Sharov, S. Mishra et al. , Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure, The American Journal of Physiology-Heart and Circulatory Physiology, vol. 295, no. 5, pp. H2149-H2155, 2008.
152. N. Kaludercic, E. Takimoto, T. Nagayama et al. , Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload, Circulation Research, vol. 106, no. 1, pp. 193-202, 2010.
153. N. Kaludercic, A. Carpi, T. Nagayama et al. , Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts, Antioxidants & Redox Signaling, vol. 20, no. 2, pp. 267-280, 2014.
154. H. H. Szeto and A. V. Birk, Serendipity and the discovery of novel compounds that restoremitochondrial plasticity, Clinical Pharmacology & Therapeutics, vol. 96, no. 6, pp. 672-683, 2014.
155. D. -F. Dai, T. Chen, H. Szeto et al. , Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy, Journal of the American College of Cardiology, vol. 58, no. 1, pp. 73-82, 2011.
156. W. Dai, J. Shi, R. C. Gupta, H. N. Sabbah, S. L. Hale, and R. A. Kloner, Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats, Journal of Cardiovascular Pharmacology, vol. 64, no. 6, pp. 543-553, 2014.
157. A. K. Chakrabarti, K. Feeney, C. Abueg et al. , Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction, American Heart Journal, vol. 165, no. 4, pp. 509. e7-514. e7, 2013.
158. V. W. Dolinsky, S. Chakrabarti, T. J. Pereira et al. , Resveratrol preventshypertension and cardiac hypertrophy in hypertensive rats and mice, Biochimica et Biophysica Acta, vol. 1832, no. 10, pp. 1723-1733, 2013.
159. J. C. Irvine, R. H. Ritchie, J. L. Favaloro, K. L. Andrews, R. E. Widdop, and B. K. Kemp-Harper, Nitroxyl (HNO): the Cinderella of the nitric oxide story, Trends in Pharmacological Sciences, vol. 29, no. 12, pp. 601-608, 2008.
160. N. Paolocci,M. I. Jackson, B. E. Lopez et al. , The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO, Pharmacology & Therapeutics, vol. 113, no. 2, pp. 442-458, 2007.
161. N. Paolocci, W. F. Saavedra, K. M. Miranda et al. , Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling, Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 18, pp. 10463-10468, 2001.
162. N. Paolocci, T. Katori, H. C. Champion et al. , Positive inotropic and lusitropic effects of HNO/NO-in failing hearts: independence fromβ-adrenergic signaling, Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5537-5542, 2003.
163. C. G. Tocchetti, W. Wang, J. P. Froehlich et al. , Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulumCa2+ cycling, Circulation Research, vol. 100, no. 1, pp. 96-104, 2007.
164. M. J. Kohr, N. Kaludercic, C. G. Tocchetti et al. , Nitroxyl enhances myocyte Ca2+ transients by exclusively targeting SR Ca2+-cycling, Frontiers in Bioscience, vol. 2, no. 2, pp. 614-626, 2010.
165. J. P. Froehlich, J. E. Mahaney, G. Keceli et al. , Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl, Biochemistry, vol. 47, no. 50, pp. 13150-13152, 2008.
166. V. Sivakumaran, B. A. Stanley, C. G. Tocchetti et al. , HNO Enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization, Antioxidants and Redox Signaling, vol. 19, no. 11, pp. 1185-1197, 2013.
167. S. Lancel, J. Zhang, A. Evangelista et al. , Nitroxyl activates SERCA in cardiacmyocytes via glutathiolation of cysteine 674, Circulation Research, vol. 104, no. 6, pp. 720-723, 2009.
168. W. D. Gao, C. I. Murray,Y. Tianet al. , Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function, Circulation Research, vol. 111, no. 8, pp. 1002-1011, 2012.
169. H. N. Sabbah, C. G. Tocchetti, M. Wang et al. , Anovel approach for the acute treatment of heart failure, Circulation: Heart Failure, vol. 6, no. 6, pp. 1250-1258, 2013.
170. L. Beckendorf and W. A. Linke, Emerging importance of oxidative stress in regulating striated muscle elasticity, Journal of Muscle Research and Cell Motility, vol. 36, no. 1, pp. 25-36, 2015.
171. M. Breitkreuz and N. Hamdani, A change of heart: oxidative stress in governing muscle function? Biophysical Reviews, vol. 7, no. 3, pp. 321-341, 2015.
172. M. A. Aon, S. Cortassa, and B. ÓRourke, Redox-optimized ROS balance: a unifying hypothesis, Biochimica et Biophysica Acta, vol. 1797, no. 6-7, pp. 865-877, 2010.
173. S. Cortassa, B. ÓRourke, and M. A. Aon, Redox-optimized ROS balance and the relationship betweenmitochondrial respiration and ROS, Biochimica et Biophysica Acta-Bioenergetics, vol. 1837, no. 2, pp. 287-295, 2014.
174. A. Nickel, M. Kohlhaas, and C. Maack, Mitochondrial reactive oxygen species production and elimination, Journal of Molecular and Cellular Cardiology, vol. 73, pp. 26-33, 2014.
175. T. Münzel, T. Gori, J. F. Keaney, C. Maack, and A. Daiber, Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications, European Heart Journal, vol. 36, no. 38, pp. 2555-2564, 2015.
176. J. A. Kirk and N. Paolocci, New redox-related arrows in the arsenal of cardiac disease treatment, Antioxidants and Redox Signaling, vol. 21, no. 14, pp. 1945-1948, 2014.